肝素结合表皮生长因子（HB-EGF）诱导角质形成细胞和成纤维细胞中Ⅶ型胶原蛋白（COL7A1）的表达：隐性营养不良型大疱性表皮松解症异体成纤维细胞治疗的潜在机制 - Suppr

Suppr

超能文献

HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa.

作者信息

Nagy Nikoletta, Almaani Noor, Tanaka Akio, Lai-Cheong Joey E, Techanukul Tanasit, Mellerio Jemima E, McGrath John A

出版信息

J Invest Dermatol. 2011 Aug;131(8):1771-4. doi: 10.1038/jid.2011.85. Epub 2011 Apr 7.

DOI:10.1038/jid.2011.85

PMID:21471992

Abstract

摘要

相似文献

HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa.肝素结合表皮生长因子（HB-EGF）诱导角质形成细胞和成纤维细胞中Ⅶ型胶原蛋白（COL7A1）的表达：隐性营养不良型大疱性表皮松解症异体成纤维细胞治疗的潜在机制

J Invest Dermatol. 2011 Aug;131(8):1771-4. doi: 10.1038/jid.2011.85. Epub 2011 Apr 7.

Cell-based therapy for RDEB: how does it work?基于细胞的 RDEB 治疗：它是如何工作的？

J Invest Dermatol. 2011 Aug;131(8):1597-9. doi: 10.1038/jid.2011.125.

Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.在营养不良性大疱性表皮松解症的COL7A1基因治疗中，成纤维细胞作为靶细胞比角质形成细胞更具潜力。

J Invest Dermatol. 2006 Apr;126(4):766-72. doi: 10.1038/sj.jid.5700117.

Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.成纤维细胞疗法治疗隐性营养不良性大疱性表皮松解症的潜力。

J Invest Dermatol. 2008 Sep;128(9):2179-89. doi: 10.1038/jid.2008.78. Epub 2008 Apr 3.

[Recessive dystrophic bullous epidermolysis: Is the etiological treatment at the streetcorner?].

Ann Dermatol Venereol. 2011 Oct;138(10):710-1. doi: 10.1016/j.annder.2011.05.002. Epub 2011 Jun 8.

Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT).使用编码COL7A1的SIN逆转录病毒载体（GENEGRAFT）进行基因校正的皮肤等效移植物，针对隐性营养不良性大疱性表皮松解症的I/II期离体基因治疗临床试验。

Hum Gene Ther Clin Dev. 2014 Jun;25(2):65-6. doi: 10.1089/humc.2014.2508.

Fibroblasts as target cells for DEB gene therapy.成纤维细胞作为DEB基因治疗的靶细胞。

J Invest Dermatol. 2006 Apr;126(4):708-10. doi: 10.1038/sj.jid.5700216.

Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.使用自失活COL7A1逆转录病毒载体的基因校正成纤维细胞疗法治疗隐性营养不良性大疱性表皮松解症

J Invest Dermatol. 2016 Jul;136(7):1346-1354. doi: 10.1016/j.jid.2016.02.811. Epub 2016 Mar 16.

Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.低毒性预处理及异基因造血祖细胞移植治疗隐性营养不良性大疱性表皮松解症

J Pediatr. 2015 Sep;167(3):765-9.e1. doi: 10.1016/j.jpeds.2015.05.051. Epub 2015 Jul 3.

Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.针对含有过早终止密码子突变的单个外显子的靶向跳跃：对选择性营养不良性大疱性表皮松解症患者基因矫正治疗的意义和潜力。

J Invest Dermatol. 2006 Dec;126(12):2614-20. doi: 10.1038/sj.jid.5700435. Epub 2006 Jun 15.

引用本文的文献

Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.隐性营养不良型大疱性表皮松解症的基因和细胞治疗用生物医学产品的现状。

Int J Mol Sci. 2024 Sep 24;25(19):10270. doi: 10.3390/ijms251910270.

Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa.基因编辑细胞：用于大疱性表皮松解症的新型异基因基因/细胞疗法。

J Appl Genet. 2024 Dec;65(4):705-726. doi: 10.1007/s13353-024-00839-2. Epub 2024 Mar 9.

Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis.大疱性表皮松解症患者皮肤病变的局部治疗管理：系统评价与荟萃分析

Healthcare (Basel). 2024 Jan 19;12(2):261. doi: 10.3390/healthcare12020261.

Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects.营养不良性大疱性表皮松解症（DEB）治疗的创新：现状与前景

Ther Clin Risk Manag. 2023 Jun 14;19:455-473. doi: 10.2147/TCRM.S386923. eCollection 2023.

Challenges in Treating Genodermatoses: New Therapies at the Horizon.遗传性皮肤病治疗面临的挑战：新疗法即将出现。

Front Pharmacol. 2022 Jan 5;12:746664. doi: 10.3389/fphar.2021.746664. eCollection 2021.

Investigational Treatments for Epidermolysis Bullosa.表皮松解性水疱症的治疗研究。

Am J Clin Dermatol. 2021 Nov;22(6):801-817. doi: 10.1007/s40257-021-00626-3. Epub 2021 Jul 22.

Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa.大疱性表皮松解症基因靶向治疗的临床前景

Dermatol Ther (Heidelb). 2021 Aug;11(4):1175-1197. doi: 10.1007/s13555-021-00561-5. Epub 2021 Jun 10.

Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.慢病毒成纤维细胞基因治疗隐性营养不良型大疱性表皮松解症的安全性和早期疗效结果。

JCI Insight. 2019 Jun 6;4(11). doi: 10.1172/jci.insight.126243.

Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.从内到外：隐性营养不良型大疱性表皮松解症的再生医学。

Pediatr Res. 2018 Jan;83(1-2):318-324. doi: 10.1038/pr.2017.244. Epub 2017 Nov 1.

Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration.促炎趋化因子和细胞因子在大疱性表皮松解症患者的水疱液分子特征中占主导地位，并影响白细胞和干细胞迁移。

J Invest Dermatol. 2017 Nov;137(11):2298-2308. doi: 10.1016/j.jid.2017.07.002. Epub 2017 Jul 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验